title: [Clinical analysis of liver non-Hodgkin's lymphoma].
abstract: OBJECTIVE
  Incidence of liver non-Hodgkin's lymphoma (NHL) is increasing. This study was to explore clinical features, diagnosis, treatment, and prognosis of liver NHL.
  
  
  METHODS
  Records of 45 patients with liver NHL treated in our hospital from Jan. 1998 to May 2002, 9.6% of all NHL patients treated in the same period, were retrospectively analyzed with statistic software package of SPSS10.0.
  
  
  RESULTS
  Of 45 patients, 32 were male,and 13 were female, the median age was 50 years. Immunophenotyping revealed that 24 cases were T cell original, 19 were B cell original, and 2 were undefined. According to International Work Formulation (IWF), 92% of 45 patients belonged to intermediate-grade. Clinical features of liver NHL were presented with fever, jaundice, hepatosplenomegalia, and liver dysfunction. Combination treatment based on chemotherapy was the major therapy. Median survival time was 4 months, overall 1-, and 2-year survival rates were 22%, and 18%.
  
  
  CONCLUSIONS
  Early diagnose liver NHL is difficult, its treatment effect and prognosis are poor, combination therapy should be given as early as possible.
authors.affiliation: Department of Medical Oncology, Beijing Cancer Hospital, School of Oncology, Peking University, Beijing, 100021, P.R.China. zhengwen824@sohu.com
authors.forename: Wen
authors.initials: W
authors.lastname: Zheng
authors.forename: Wei-Ben
authors.initials: WB
authors.lastname: Yong
authors.forename: Jun
authors.initials: J
authors.lastname: Zhu
authors.forename: Yun-Tao
authors.initials: YT
authors.lastname: Zhang
authors.forename: Xiao-Pei
authors.initials: XP
authors.lastname: Wang
authors.forename: Yan
authors.initials: Y
authors.lastname: Xie
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy*; D016393:Lymphoma, B-Cell / Q000097:blood / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy*; D016399:Lymphoma, T-Cell / Q000097:blood / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin; D011241:Prednisone